Results 191 to 200 of about 103,862 (301)

Poly(ADP-ribose) polymerase (PARP) inhibitors in cardiovascular, and cerebrovascular diseases: mechanisms, current trends and challenge for clinical translation. [PDF]

PeerJ
Fan J, Song Y.
europepmc   +1 more source

SOD2‐Superoxide Metabolic Axis Regulates Mitophagy and Modulates TKIs Sensitivity in Head and Neck Squamous Cell Carcinoma

Cancer Science, EarlyView.
Our findings provide compelling evidence that the SOD2‐superoxide metabolic axis functions as a mitochondrial redox checkpoint that governs mitophagy and ultimately shapes TKI sensitivity. ABSTRACT Superoxide dismutase 2 (SOD2) has been implicated in head and neck squamous cell carcinoma (HNSCC), yet its mechanistic contribution in regulating tumor ...
Wan‐Hang Zhou, Shuo‐Jin Huang, An‐Xun Wang   +2 more
wiley   +1 more source

Efficacy and safety of PARP inhibitors monotherapy or combination therapy with anti-angiogenics in ovarian cancer: a network meta-analysis. [PDF]

Front Oncol
Liu Y, Ren T, Wang X, Wang Y, Tang L, Cao W.   +5 more
europepmc   +1 more source

A novel glucose beta‐hydroxybutyrate combination improves hypoglycaemia recovery and patient‐reported outcomes in type 1 diabetes

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Hypoglycaemia remains a major barrier to optimal diabetes management. Current treatments based on simple sugars have limitations, including rapid glucose fluctuations and persistent neuroglycopenic symptoms. We investigated FLO23011, a novel multi‐substrate energy formulation containing glucose and beta‐hydroxybutyrate, as a superior ...
D. Russell‐Jones, V. Smout, S. Roy, G. Myers, R. Littlewood, F. Shojaee‐Moradie   +5 more
wiley   +1 more source

Twelve mutations, three trials, and five different labels: PARP inhibitors regulatory inconsistencies in prostate cancers. [PDF]

EClinicalMedicine
Barjesteh van Waalwijk van Doorn-Khosrovani S, Westgeest HM, Olivier T.   +2 more
europepmc   +1 more source

244 PARP inhibitors

European Journal of Cancer Supplements, 2010
openaire   +1 more source

Targeting the Menin–KMT2A Axis in Acute Leukemia: From Epigenetic Dependency to Clinical Translation

European Journal of Haematology, EarlyView.
ABSTRACT Acute leukemias characterized by a shared epigenetic dependency on the menin–KMT2A axis rely on aberrant HOX‐driven transcriptional programs that sustain leukemic self‐renewal and impair differentiation. This dependency is most evident in KMT2A‐rearranged and NPM1‐mutated acute myeloid leukemia (AML), but also extends to other HOX‐dependent ...
Antonella Bruzzese, Ernesto Vigna, Enrica Antonia Martino, Santino Caserta, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Mamdouh Skafi, Nicola Amodio, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Toxicities of PARP inhibitors in genitourinary cancers. [PDF]

Curr Opin Urol
Szalontai J, Szarvas T, Miszczyk M, Nyirády P, Shariat SF, Fazekas T.   +5 more
europepmc   +1 more source

Automodification of N‐terminal serine residues facilitates PARP2 release from DNA

The FEBS Journal, EarlyView.
PARP2 is involved in detecting DNA damage and its N‐terminal role is largely unknown. Based on biochemical and biophysical data, our findings suggest that in the presence of HPF1, N‐terminal serine 8 and 73 are enriched in auto‐ADP‐ribosylation. Our results provide insight into the mechanistic role of PARP2 N‐terminus in the PARylation‐dependent ...
Saurabh Singh Dhakar, Albert Galera‐Prat, Jin Cai, Julia Preisser, Tiila‐Riikka Kiema, Andreas Ladurner, Lari Lehtiö   +6 more
wiley   +1 more source

Global research trends in PARP inhibitors for ovarian cancer: a bibliometric analysis. [PDF]

Discov Oncol
Wang X, Ding G, He J, Huang Y, Wang Q.
europepmc   +1 more source